Skip to content
Search

Latest Stories

Any new coronavirus vaccine will take two years: Novartis CEO   

Any vaccine to fight the new coronavirus will not be ready for use for at least two years, the chief executive of Swiss pharmaceutical company Novartis , which no longer makes vaccines itself, told a German newspaper.

Novartis sold its vaccine business in 2015 to GlaxoSmithKline, one of many companies around the world now racing to make a drug. Some companies are already testing vaccine candidates on humans.


"The results of the first clinical studies on the vaccine candidates should be available in autumn," Novartis CEO Vas Narasimhan told Frankfurter Allgemeine Zeitung (FAZ). "If everything goes as we hope, it will take 24 months before we have a vaccine."

For instance, Moderna Inc has sped up plans for its experimental Covid-19 vaccine and said it expected to start a late-stage trial in early summer.

But experts have said no vaccine is expected to be ready for use until at least 2021, as they must be widely tested in humans before being administered to hundreds of millions, if not billions, of people to prevent infection.

Narasimhan, who headed development at Novartis's vaccine business before the Basel-based company concluded it was too small to keep and should be unloaded, said producing enough vaccine for the world would also be a challenge.

He said building a new factory usually took three or four years. "That's way too long," he told FAZ. "We have to use the existing production network to produce large quantities quickly."

(Reuters)

More For You

Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
After US and EU, UK approves Bavarian Nordic’s chikungunya vaccine

Bavarian Nordic plans to launch the vaccine in the UK in summer 2025

Getty Images

Chikungunya vaccine Vimkunya approved for use in the UK

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Vimkunya, a vaccine developed by Bavarian Nordic A/S to prevent chikungunya disease in people aged 12 years and older.

The UK approval follows earlier approvals by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025, making this the third regulatory green light for the vaccine.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less
Many patients report inaccuracies or missing details in their NHS medical records

Inaccurate information can result in serious harm or even death, warns Healthwatch England.

Image Credit: Getty Images

1 in 4 adults have spotted errors in their NHS medical records, survey finds

Healthwatch England has raised the alarm over the risks posed by inaccurate medical records as research reveals widespread errors in NHS patient information.

Commissioned by Healthwatch England and conducted by BMG Research, the survey polled a representative sample of 1,800 adults in England between 24 and 27 March 2025.

Keep ReadingShow less
Lib Dems condemn rising unsolved crimes, say shoplifting and burglary ‘effectively decriminalised’

Leicestershire police recorded the lowest charge rate for shoplifting in the country.

Gettyimages

Shoplifting and burglary ‘effectively decriminalised’, warn Lib Dems as unsolved crimes soar

The Liberal Democrats have raised alarm over what they describe as the “decriminalisation” of burglary and shoplifting, as new data reveals that the vast majority of such offences across Britain are going unsolved.

Figures revealed by the House of Commons Library research, commissioned by the party, showed that only 5.25 per cent of shoplifting offences in London last year led to a suspect being charged.

Keep ReadingShow less